Given the importance of TLR7 signaling in driving human lupus, phase II clinical trials evaluating the efficacy and safety of orally administered enpatoran in SLE and cutaneous lupus erythematosus have been initiated (NCT05162586, NCT05540327). Here, TLR7 is linked to systemic lupus erythematosus.